Skip to main content

Advertisement

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study

Fig. 2

Effects of secukinumab treatment on the inflammatory changes in the joints of patients with psoriatic arthritis. a Comparison of inflammatory changes in the joints of psoriatic arthritis (PsA) patients using magnetic resonance imaging (MRI) at baseline (BL) and after 24 weeks (Wk24) of secukinumab treatment. Psoriatic arthritis MRI scores (PsAMRIS) for synovitis and total PsAMRIS scores are shown. b Representative coronal T1-weighted fat-suppressed post-gadolinium MRI images of the hand of the same patient with PsA at baseline and after 24 weeks are depicted. Baseline image shows synovitis (arrows) and periarticular inflammation at enthesial sites (arrowheads), which resolved after 24 weeks of secukinumab treatment. c Comparison of inflammatory changes in the joints of PsA patients using power Doppler ultrasound (PDUS) at baseline (BL) and after 24 weeks (Wk24) of secukinumab treatment. OMERACT ultrasound scores for synovial hypertrophy and power Doppler activity as well as global OMERACT ultrasound scores are shown. Data are presented as median and interquartile ranges. *P ≤0.05; **P ≤0.01

Back to article page